2-氨基-3-溴吡嗪 | 21943-12-4

• 物质功能分类: 医药中间体 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-3-溴吡嗪
• 英文名称: 3-bromopyrazin-2-amine
• 英文别名: 2-amino-3-bromopyrazine
• CAS: 21943-12-4
• 化学式: C₄H₄BrN₃
• mdl: MFCD09909692
• 分子量: 174.0
• InChiKey: BFEUGUAUYFATRV-UHFFFAOYSA-N

物化性质

• 沸点：
  275.6±35.0 °C(Predicted)
• 密度：
  1.844±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-3-bromopyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-3-bromopyrazine
CAS number: 21943-12-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H4BrN3
Molecular weight: 174.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-3-溴吡嗪 在 氨 、 铜 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以2.05 g的产率得到2,3-二氨基哌嗪
  参考文献：
  名称：

  Purine analogues as amplifiers of phleomycin. VII. Some 1H-imidazo-[4,5-b]pyrazines and related compounds

  摘要：

  从吡嗪-2,3-二胺制备 2-羟基- 和 2-巯基-1H-咪唑并[4,5-bl-吡嗪]的制备方法。 描述。用碘甲烷和重氮甲烷将 1H-咪唑并[4,5-b]吡嗪-2(3H)-硫酮甲基化后 甲基碘和重氮甲烷进行甲基化，得到了一些 S、N1、N3 和 N4 甲基衍生物；以及 1H-咪唑并[4,5-b]吡嗪- 2(3H)-酮与重氮甲烷反应生成的产物涉及 O、N1、N3 和 N4 甲基化。这些产物显示出轻微的活性 但苯并噻唑（10b）和（10c）（作为氢溴酸盐 氢溴酸盐）分别显示出三星级和四星级活性。

  DOI：

  10.1071/ch9822299
• 作为产物：
  描述：

  氨基吡嗪 在 bromodioxane 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以48%的产率得到2-氨基-5-溴吡嗪
  参考文献：
  名称：

  2-氨基吡嗪的高效卤化

  摘要：

  2-氨基吡嗪在不同的反应条件下被 NIS、NCS 和 NBS 卤化。以乙腈为溶剂，氯化和溴化反应收率良好。然而，碘化的收率很低。毫无疑问，单卤化和二卤化的最佳条件是短时间使用 NBS、乙腈和微波辅助。3,5-Dibromo-2-aminopyrazine 是合成氮杂环的优良官能化原料。

  DOI：

  10.1055/s-0039-1690183

文献信息

• 具有取代吡嗪并咪唑类衍生物,其制备及其在 医药上的应用
  申请人：陈剑

  公开号：CN107056789B

  公开（公告）日：2019-03-29

  本发明公开了具有取代吡嗪并咪唑类衍生物，其制备及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的新的衍生物及其可药用的盐或含有其的药物组合物，及其制备方法。本发明还公开了所述衍生物及其可药用的盐或含有其的药物组合物在Bruton酪氨酸激酶抑制剂，和在制备治疗和/或预防肿瘤与炎症等疾病的药物中的应用。其中通式(I)的各取代基同说明书中的定义相同。
• [EN] SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] COMPOSÉS TÉTRAHYDROQUINOLINONE SUBSTITUÉS EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2016185342A1

  公开（公告）日：2016-11-24

  The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了公式（I）的取代四氢喹啉酮及相关化合物，作为视黄酸受体相关孤儿受体（RORs）的调节剂，在RORγ调节剂方面具有治疗上的用途。这些化合物在治疗和预防疾病和/或紊乱方面具有用途，特别是它们在由RORγ受体介导的疾病和/或紊乱中的用途。本发明还提供了这些化合物的制备以及包含至少一种取代四氢喹啉酮或相关化合物的制剂和药物配方，以及其所用的药学上可接受的载体、稀释剂或赋形剂。
• Lead identification and structure–activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists
  作者：Afjal H. Miah、Royston C. B. Copley、Daniel O'Flynn、Jonathan M. Percy、Panayiotis A. Procopiou

  DOI：10.1039/c3ob42443j

  日期：——

  A knowledge-based library of aryl 2,3-dichlorophenylsulfonamides was synthesised and screened as human CCR4 antagonists, in order to identify a suitable hit for the start of a lead-optimisation programme. X-ray diffraction studies were used to identify the pyrazole ring as a moiety that could bring about intramolecular hydrogen bonding with the sulfonamide NH and provide a clip or orthogonal conformation that was believed to be the preferred active conformation. Replacement of the core phenyl ring with a pyridine, and replacement of the 2,3-dichlorobenzenesulfonamide with 5-chlorothiophenesulfonamide provided compound 33 which has excellent physicochemical properties and represents a good starting point for a lead optimisation programme. Electronic structure calculations indicated that the preference for the clip or orthogonal conformation found in the small molecule crystal structures of 7 and 14 was in agreement with the order of potency in the biological assay.

  基于知识的芳基2,3-二氯苯磺酰胺类化合物库被合成并筛选为人CCR4拮抗剂，旨在确定一个适合作为先导优化计划起点的候选化合物。X射线衍射研究用于鉴定吡唑环为一个可以通过分子内氢键与磺酰胺NH结合并提供被认为是优选活性构象的夹子或正交构象的基团。用吡啶替换核心苯环，并用5-氯噻吩磺酰胺替换2,3-二氯苯磺酰胺得到了化合物33，其具有优异的物化性质，并代表了一个良好的先导优化计划起点。电子结构计算表明，小分子晶体结构中发现的夹子或正交构象的偏好与生物测定中的效力顺序一致。
• FUSED RING HETEROARYL COMPOUNDS AS RIPK1 INHIBITORS
  申请人：BiSiChem Co., Ltd.

  公开号：US20210040115A1

  公开（公告）日：2021-02-11

  The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of RIPK1 and the therapeutic methods.

  本发明提供了式I表示的新颖取代杂环化合物，或其药学上可接受的盐、溶剂化物、多晶型物、酯、互变异构体或前药，以及包含这些化合物的组合物。所提供的化合物可用作RIPK1抑制剂及治疗方法。
• 一种2-氨基-5-杂芳基取代的吡嗪衍生物及其用途
  申请人：徐新杰

  公开号：CN112851639A

  公开（公告）日：2021-05-28

  本发明提供一种具有式1所示化学结构的2‑氨基‑5‑杂芳基取代的吡嗪衍生物，包含其的药物制剂，及其在治疗或预防疟疾的药物中的应用，本发明的化合物具有显著优于现有技术的对抗恶性疟原虫增殖和对抗不同菌株的恶性疟原虫的效果，且具有更长的半衰期，更低的血浆清除率，更高的分布体积和更好的口服生物利用度。